The Case for Expensive Antibiotics
The Case for Expensive Antibiotics
What's New · SpokenLayer
September 21, 20187m 44s
Audio is streamed directly from the publisher (dovetail.prxu.org) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A handful of years ago, a small pharmaceutical company quietly acquired the rights to an old but commonly used antibiotic. Few noticed until last week, when the new owner did something that’s recently become common in the world of pharmaceuticals: It abruptly raised the price. A lot. The manufacturer is called Nostrum Laboratories, and the drug for which it hiked the price—by more than 400 percent—is called nitrofurantoin.
Learn about your ad choices: dovetail.prx.org/ad-choices